Aroa Biosurgery Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Aroa Biosurgery yıllık ortalama 11.5% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 12.6% annual. Gelirler yılda ortalama 29.2% oranında büyüyor .

Anahtar bilgiler

11.5%

Kazanç büyüme oranı

79.4%

EPS büyüme oranı

Biotechs Sektör Büyümesi9.6%
Gelir büyüme oranı29.2%
Özkaynak getirisi-11.2%
Net Marj-15.4%
Sonraki Kazanç Güncellemesi25 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn

Nov 13
We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn

Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper

Aug 22
Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper

Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Jun 12
Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Mar 25
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Jan 30
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Nov 14
Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Nov 02
Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

Oct 25
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

May 13
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

May 26
Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Mar 22
An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Feb 24
Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Feb 24
Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Dec 16
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Gelir ve Gider Dağılımı

Aroa Biosurgery nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

ASX:ARX Gelir, gider ve kazançlar (NZD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 2469-11629
31 Dec 2367-9599
30 Sep 2366-85610
30 Jun 2365-45210
31 Mar 236304811
31 Dec 2257-14211
30 Sep 2251-23711
30 Jun 2245-53410
31 Mar 2240-8318
31 Dec 2135-10288
30 Sep 2131-11267
30 Jun 2127-15247
31 Mar 2122-19226
31 Dec 2022-19216
30 Sep 2021-19205
30 Jun 2023-12185
31 Mar 2025-6175
31 Mar 19241125
31 Mar 1811-143

Kaliteli Kazançlar: ARX şu anda kârlı değil.

Büyüyen Kar Marjı: ARX şu anda kârlı değil.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ARX kârlı değildir, ancak son 5 yılda zararlarını yılda 11.5% oranında azaltmıştır.

Büyüme Hızlandırma: ARX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: ARX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 2.6% ) karşılaştırılması zorlaşıyor.


Özkaynak Getirisi

Yüksek ROE: ARX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -11.19% ) sahiptir.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin